Clinicians Trial brief

TRIUMPH-4: weight & knee osteoarthritis

Originally posted Dec 2025 · By Joe Zucchi, PA-C, MPAS

Download JPG ↓Original LinkedIn post ↗

1280 × 955 px · PDF includes the original image and a link to this page.

Joe’s commentary

About this visual

Joe’s original visual on retatrutide efficacy, pain outcomes, and tolerability.

The Phase 3 TRIUMPH-4 data for Eli Lilly's retatrutide is out, and the results in patients with obesity and knee OA are very exciting. We're seeing incredible weight loss (mean reduction of 28.7% at the 12 mg dose) alongside a substantial ~76% improvement in WOMAC pain scores.

Beyond weight and pain, the cardiovascular marker improvements are noteworthy, including a decrease in systolic blood pressure of 14.0 mmHg at the highest dose.

As with any therapy, the tolerability profile is an important consideration. This infographic provides a snapshot of the key efficacy and safety data.

Sources & further reading

Original LinkedIn post and discussion ↗

Additional references appear in the infographic and the original LinkedIn discussion.

Related visuals

TRIUMPH-4: weight & knee osteoarthritis

Pinch to zoom on touch devices. Open full image ↗